GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 67.29 USD | -0.90% |
|
-0.53% | -16.94% |
ETFs positioned on Gilead Sciences, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.92% | 9 M€ | +10.64% | ||
| 0.92% | 204 M€ | +10.54% | ||
| 0.87% | 3 M€ | +15.16% | - | |
| 0.87% | 4 M€ | -.--% | - | |
| 0.87% | 13 M€ | -.--% | - | |
| 0.83% | 375 M€ | +9.39% | ||
| 0.77% | 15 M€ | 0.00% | - | |
| 0.73% | 3,859 M€ | +18.82% | - | |
| 0.73% | 469 M€ | -2.05% | ||
| 0.66% | 8 M€ | +5.48% | - | |
| 0.63% | 727 M€ | +9.29% | ||
| 0.62% | 2 M€ | +21.73% | - | |
| 0.60% | 92 M€ | +0.06% | - | |
| 0.57% | 25 M€ | +4.69% | - | |
| 0.52% | 5 M€ | -.--% | - | |
| 0.51% | 219 M€ | +17.17% | - | |
| 0.51% | 1,448 M€ | -.--% | - | |
| 0.50% | 330 M€ | -.--% | ||
| 0.47% | 2 M€ | +14.69% | - | |
| 0.44% | 22 M€ | +16.35% | ||
| 0.42% | 7 M€ | +6.22% | - | |
| 0.40% | 9 M€ | +11.35% | - | |
| 0.40% | 655 M€ | -.--% | - | |
| 0.40% | 273 M€ | -.--% | ||
| 0.40% | 1,174 M€ | +23.54% | ||
| 0.40% | 276 M€ | +11.40% | - | |
| 0.37% | 368 M€ | +22.69% | - | |
| 0.37% | 414 M€ | +13.03% | - | |
| 0.37% | 1,006 M€ | -.--% | - | |
| 0.37% | 2,383 M€ | +14.65% | ||
| 0.36% | 1 M€ | +0.04% |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.29
USD
Average target price
82.93
USD
Spread / Average Target
+23.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.94% | 83.83B | |
| +37.78% | 723B | |
| +30.47% | 598B | |
| -3.51% | 364B | |
| +19.94% | 331B | |
| +5.14% | 288B | |
| +16.47% | 244B | |
| -4.58% | 208B | |
| +10.07% | 210B | |
| +9.32% | 169B |
- Stock Market
- Equities
- GILD Stock
- Funds and ETFs Gilead Sciences, Inc.